MMF Shows Promise in Juvenile Scleroderma
Mycophenolate mofetil demonstrated comparable disease control with fewer adverse effects.
-
By
-
Kathryn Wighton
-
February 2, 2026
-
Clinical Scorecard: MMF Shows Promise in Juvenile Scleroderma
At a Glance
| Category | Detail |
|---|
| Condition | Juvenile Localized Scleroderma (JLS) |
| Key Mechanisms | Mycophenolate mofetil (MMF) and methotrexate (MTX) are used to reduce disease activity. |
| Target Population | Patients with juvenile localized scleroderma, onset prior to age 18. |
| Care Setting | Pediatric dermatology clinic. |
Key Highlights
- MMF demonstrated similar effectiveness to MTX in reducing disease activity.
- MMF caused significantly fewer adverse effects compared to MTX.
- Inactive disease status achieved by all treatment groups within 12 months.
- Disease flare occurred in 25% of patients, with no significant differences between groups.
- Longitudinal analysis utilized linear mixed-effects models.
Guideline-Based Recommendations
Diagnosis
- Use the Localized Scleroderma Cutaneous Assessment Tool for clinical evaluations.
Management
- Consider MMF as a potential first-line treatment for JLS.
Monitoring & Follow-up
- Assess disease activity using the modified Localized Scleroderma Skin Severity Index (mLoSSI).
Risks
- Monitor for adverse effects, particularly with MTX, including nausea and fatigue.
Patient & Prescribing Data
114 patients with juvenile localized scleroderma.
MMF was often initiated after longer disease duration or MTX intolerance.
Clinical Best Practices
- Conduct prospective, randomized, noninferiority trials to confirm findings.
- Utilize validated patient-reported measures for assessing adverse effects.
References
